Argenx SE
ARGX
Clasificación en acciones
#473
argenx SE, a biotechnology company established in Amsterdam, the Netherlands,... argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.
Precio por acción
$820.57
Capitalización bursátil
$51.43B
Cambio (1 día)
0.17%
Cambio (1 año)
-2.74%
País
NL
Comercio Argenx SE (ARGX)
Categoría
Healthcare
Margen Operativo de Argenx SE (ARGX)
Margen Operativo al October 2026 TTM: 28.81%
Según los informes financieros más recientes y el precio de las acciones de Argenx SE, el margen operativo actual (TTM) es 28.81%. Al final de 2023, el margen operativo era -34.66%.
Historial de Margen Operativo de Argenx SE desde 2010 hasta 2026
Margen Operativo al final de cada año
| Año | Margen Operativo | Cambiar |
|---|---|---|
| 2026 (TTM) | 28.81% | -2,981.00% |
| 2024 | -1.00% | -97.11% |
| 2023 | -34.66% | -80.24% |
| 2022 | -175.37% | 150.06% |
| 2021 | -70.13% | -93.94% |
| 2020 | -1,158.06% | 356.85% |
| 2019 | -253.49% | -33.47% |
| 2018 | -381.01% | 505.07% |
| 2017 | -62.97% | -56.74% |
| 2016 | -145.56% | -36.07% |
| 2015 | -227.68% | -20.40% |
| 2014 | -286.02% | 22.90% |
| 2013 | -232.72% | -61.77% |
| 2012 | -608.78% | 88.15% |
| 2011 | -323.56% | 0.00% |
| 2010 | 0.00% | 0.00% |
Margen Operativo de empresas similares o competidoras
| Empresa | Margen Operativo | Diferencia de Margen Operativo | País |
|---|---|---|---|
| 38.59% | -98.66% |
US
|
|
| -149.01% | -105.17% |
US
|
|
| 25.57% | -99.11% |
AU
|
|
| 0.00% | - |
CH
|
|
| 31.23% | -98.92% |
BE
|
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.